These findings on differential methylation in AD mark oxytocin as a potential early biomarker and treatment angle for AD, the latter of which is even more interesting, with oxytocin being a Food and Drug Agency (FDA)-approved drug for aiding facilitation of labor in antepartum to strengthen uterine contractions and postpartum to deliver the placenta and control postpartum hemorrhage [26]. The gene discussed is OXT; the disease is hemorrhage.